Article by Yippee-Ki-Yay

Should you invest in Xvivo Perfusion AB in 2025? Our detailed analysis

Buy signal | Free publication | 9 Oct 2025

Hello investors and stock market enthusiasts! Today, we're diving into the figures for Xvivo Perfusion AB, a Swedish gem operating in the medical field. If you like innovative companies, whether you're a seasoned trader or a beginner, this article is for you. We'll be dissecting its financial health, performance and prospects, all with a touch of humour to keep it light-hearted. Hold on tight, here we go for a comprehensive overview!

Introducing Xvivo Perfusion AB

Xvivo Perfusion is a Swedish company specialising in organ perfusion solutions. Imagine: their technologies make it possible to keep organs alive outside the human body prior to transplantation. It's science fiction become reality! Listed on the stock exchange, this company has shown impressive growth, with revenue skyrocketing in recent years. In 2024, it reached SEK 822.41 million (Swedish krona), compared to just SEK 179.86 million in 2020. A meteoric rise, almost as if it had swallowed financial steroids.

Their secret? Solid R&D, innovative products, and international expansion. Xvivo is not just a start-up; it is an established player that aims to revolutionise organ transplants. And clearly, the markets love it.

Quality analysis of Xvivo Perfusion AB

We examined five key criteria to rate the company on a scale of 1 to 5. Here is the verdict, with detailed explanations for each category.

1. Revenue (CA) – Rating: 5/5

Xvivo's revenue has skyrocketed: +47% average annual growth between 2020 and 2024. In 2024, it reached SEK 822.41 million, up from SEK 597.54 million in 2023. That's solid, almost too good to be true. Demand for their medical products seems insatiable, and their business strategy is paying off. No concerns here – it's 10/10 in terms of growth.

2. Net profit – Rating: 4/5

In 2024, net profit amounted to SEK 172.18 million, a massive improvement on the SEK 91.98 million recorded in 2023 (note that there is an inconsistency in the data: 919.82 appears to be a data entry error). Even in 2022 and 2021, the company was profitable, after a dip in 2020, possibly due to the pandemic. Profitability is there, but with slight volatility. We give it a 4/5 because it is robust, but not yet perfectly stable.

3. Debt – Rating: 5/5

Xvivo is virtually debt-free! Total debt in 2024 is only SEK 34.04 million, a tiny fraction of total assets (SEK 2,402.74 million). With a negligible debt ratio and high liquidity (SEK 415.22 million), it is a very healthy company. No stress on repayments – it deserves a 5/5.

4. Return on equity (ROE) – Rating: 3/5

ROE (return on equity) is calculated as: net profit / equity. In 2024, it is around 8% (172.18 / 2,156.77). This is acceptable, but not exceptional. In 2023, it was higher (around 20%), but equity increased due to capital increases. Profitability is there, but it could be optimised. We give it 3/5 – not bad, but could do better.

5. Market performance – Rating: 4/5

Xvivo's share price has risen from around SEK 23 in 2019 (tangible value per share) to SEK 169.20 today. That's an increase of more than 600% in five years! Investors who jumped on the bandwagon must be smiling. The valuation is supported by growth and innovation. One small caveat: shares like these can be volatile. Score: 4/5.

Forecasts for the coming years

According to the data, the forecasts for Xvivo are optimistic:

  • 2025: Estimated turnover of SEK 1,023.5 million, EPS of 5.4.
  • 2026: Turnover of SEK 1,404.5 million, EPS of 8.16.
  • 2027: Revenue of SEK 2,258 million, EPS not specified.

Growth is expected to continue, driven by medical demand and geographical expansion.

Estimated share value in 2026 and 2027

With an expected EPS of SEK 8.16 in 2027 and a historical P/E ratio of around 30-35x (typical for medical growth stocks), the share price could reach:

  • 2026: EPS of 5.4 → Estimated price = 5.4 * 35 = SEK 189.
  • 2027: EPS of 8.16 → Estimated price = 8.16 * 35 = SEK 285.

That's a potential increase of 68% by 2027! Of course, this depends on market conditions.

General conclusion

Xvivo Perfusion AB is a quality company, rated 4.2/5 overall. Its strengths: explosive sales growth, low debt, and innovation that changes lives. Points to watch: average ROE and possible volatility. For patient investors, this is a good bet for 2026-2027.

So, are you ready to take the plunge? As always, do your research and don't bet everything on a single move. But if you're looking for a stock that combines sense and performance, Xvivo could well be your next winning move. Invest smart, stay cool! 😎

  • Signal : Buy
  • Budget/Investment : Medium
  • Reinforcement required : No
  • Exposure : Medium
  • Horizon : 2 to 3 years
  • Potential profitability : +68%
  • Ref. ISIN code : SE0004840718
  • Article updated on 14/04/2026: We have just sold our shares in Xvivo Perfusion AB, having achieved a return of +65.7% over seven months. 🤩 (Purchased in October at SEK 169 per share)